Astellas Pharma Inc. (TYO:4503)
Japan
· Delayed Price · Currency is JPY 1,465.50
+12.00 (0.83%)
Feb 21, 2025, 3:30 PM JST
Astellas Pharma Revenue
Astellas Pharma had revenue of 517.41B JPY in the quarter ending December 31, 2024, with 22.63% growth. This brings the company's revenue in the last twelve months to 1.87T, up 21.01% year-over-year. In the fiscal year ending March 31, 2024, Astellas Pharma had annual revenue of 1.60T with 5.60% growth.
Revenue (ttm)
1,867.63B
Revenue Growth
+21.01%
P/S Ratio
1.41
Revenue / Employee
126.58M
Employees
14,754
Market Cap
2,623.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 1,603.67B | 85.05B | 5.60% |
| Mar 31, 2023 | 1,518.62B | 222.46B | 17.16% |
| Mar 31, 2022 | 1,296.16B | 46.64B | 3.73% |
| Mar 31, 2021 | 1,249.53B | -51.32B | -3.94% |
| Mar 31, 2020 | 1,300.84B | -5.51B | -0.42% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,170.61B |
| Takeda Pharmaceutical Company | 4,579.02B |
| Daiichi Sankyo Company | 1,795.99B |
| HOYA Corporation | 837.44B |
| Terumo | 1,011.15B |
| Otsuka Holdings | 2,329.86B |
| Olympus | 993.33B |
| Shionogi & | 456.87B |
Astellas Pharma News
- 9 days ago - U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy - PRNewsWire
- 10 days ago - Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo - Benzinga
- 11 days ago - Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC) - Benzinga
- 13 days ago - Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Astellas Pharma Inc. 2024 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 17 days ago - Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan - PRNewsWire
- 18 days ago - Astellas Pharma Non-GAAP EPS of ¥124.60, revenue of ¥1453.03B; updates FY outlook - Seeking Alpha
- 18 days ago - Astellas Makes Announcement about Management Structure - PRNewsWire